Amgen (AMGN) Presents New Repatha Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Amgen (AMGN) data supports long-term growth potential says analyst
November 8, 2022 10:37 AM ESTAmgen (NASDAQ: AMGN) reported new analysis from its Phase 3 FOURIER and FOURIER open label extension (OLE) studies of Repatha on Tuesday, stating that the data reinforces long-term efficacy and the consistent safety profile.
Amgen shares are up more than 5% following the... More
Amgen (AMGN) PT Raised to $325 at Jefferies Following AMG-133 Update
November 8, 2022 8:16 AM ESTJefferies analyst Michael Yee raised the price target on Amgen (NASDAQ: AMGN) to $325.00 (from $300.00) while maintaining a Buy rating.
The analyst commented, "AMGN update looks positive and consistent w/ our Buy, with valuation likely to go up with AMG-133 for obesity... More
